Ayvakit
Ayvakit ingredients
| Active ingredient | Strength |
|---|---|
| Avapritinib | 300 mg/1, 100 mg/1, 200 mg/1, 25 mg/1, 50 mg/1 |
What Ayvakit is used for
The FDA lists the approved uses on the official label (below). In the EU, avapritinib is approved as Ayvakyt for:
Unresectable or metastatic gastrointestinal stromal tumour (GIST) AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation. Advanced systemic mastocytosis (AdvSM) AYVAKYT is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy. Indolent systemic mastocytosis (ISM) AYVAKYT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment (see section 5.1).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ayvakit
- Generic name
- Avapritinib
- Made by
- Blueprint Medicines Corporation
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA212608
- On the US market since
- 2020
Official information
- MedlinePlus drug information (search for Avapritinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ayvakit?
Ayvakit (Avapritinib) is a cancer medicine made by Blueprint Medicines Corporation, approved by the US FDA.
What are the ingredients of Ayvakit?
Ayvakit contains Avapritinib (300 mg/1, 100 mg/1, 200 mg/1, 25 mg/1, 50 mg/1).
Is Ayvakit approved in Europe?
The same active substance is approved in the EU as Ayvakyt.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA